Executive Vice President for Development, Novo Nordisk
Appears in 1 story
Overseeing denecimig's late-stage program and regulatory filings
People with hemophilia A can bleed for hours from a small cut and bleed inside their joints for no clear reason. Novo Nordisk says its experimental injection, denecimig, kept most patients bleed-free in a long-term trial: about 71% of adults and teens and about 89% of children had zero treated bleeds.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?